These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 184773)

  • 1. Changes in plasma lipoproteins in subjects treated with the bile acid-sequestering resin polidexide (Secholex).
    Simons LA; Williams PF
    Aust N Z J Med; 1976 Apr; 6(2):127-30. PubMed ID: 184773
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic effects of the bile acid sequestrant polidexide (SecholexR) in man.
    Simons LA; Myant NB
    Adv Exp Med Biol; 1977; 82():188-90. PubMed ID: 200089
    [No Abstract]   [Full Text] [Related]  

  • 3. Effect of treatment with a bile-sequestering agent (Secholex) on intestinal absorption, duodenal bile acids, and plasma lipids.
    Ritland S; Fausa O; Gjone E; Blomhoff JP; Skrede S; Lanner A
    Scand J Gastroenterol; 1975; 10(8):791-800. PubMed ID: 173015
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of hypercholesterolemia with Secholex. A long-term clinical trial and comparison with cholestyramine.
    Nikkila EA; Miettinen TA; Lanner A
    Atherosclerosis; 1976 Sep; 24(3):407-19. PubMed ID: 971343
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in plasma lipoprotein lipids in hypercholesterolaemic patients treated with the bile acid-sequestering resin, colestipol.
    Clifton-Bligh P; Miller NE; Nestel PJ
    Clin Sci Mol Med; 1974 Dec; 47(6):547-57. PubMed ID: 4375013
    [No Abstract]   [Full Text] [Related]  

  • 6. Treatment of hyperlipoproteinaemia type II A with a new anion exchange resin secholex.
    Gustafson A; Lanner A
    Eur J Clin Pharmacol; 1974; 7(1):65-9. PubMed ID: 4369397
    [No Abstract]   [Full Text] [Related]  

  • 7. Secholex, Clofibrate and taurine in hyperlipidaemia.
    Howard AN; Evans RJ
    Atherosclerosis; 1974; 20(1):105-16. PubMed ID: 4376405
    [No Abstract]   [Full Text] [Related]  

  • 8. Hypertriglyceridemia: a contraindication to the use of bile acid binding resins.
    Crouse JR
    Am J Med; 1987 Aug; 83(2):243-8. PubMed ID: 3618626
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Treatment of hyperlipoproteinemias (author's transl)].
    Crepaldi G; Fellin R; Briani G; Baggio G; Baiocchi MR
    G Ital Cardiol; 1974; 4(3):332-40. PubMed ID: 4367439
    [No Abstract]   [Full Text] [Related]  

  • 10. Colestipol and cholestyramine resin. Comparative effects in familial type II hyperlipoproteinemia.
    Glueck CJ; Ford S; Scheel D; Steiner P
    JAMA; 1972 Nov; 222(6):676-81. PubMed ID: 4562098
    [No Abstract]   [Full Text] [Related]  

  • 11. An effective treatment of hypercholesterolaemia using a combination of Secholex and clofibrate.
    Evans RJ; Howard AN; Hyams DE
    Angiology; 1973 Jan; 24(1):22-8. PubMed ID: 4694031
    [No Abstract]   [Full Text] [Related]  

  • 12. The combined use of clofibrate and anion exchange in the treatment of hypercholesterolemia.
    Howard AN; Hyams DE; Evans C
    Adv Exp Med Biol; 1972; 26(0):179-87. PubMed ID: 4679724
    [No Abstract]   [Full Text] [Related]  

  • 13. Abnormal low density lipoproteins in children with familial hypercholesterolemia--effect of polyanion exchange resins.
    Mordasini R; Twelsiek F; Oster P; Schellenberg B; Raetzer H; Heuck CC; Schlierf G
    Klin Wochenschr; 1978 Aug; 56(16):805-8. PubMed ID: 211316
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of cholestyramine and nicotinic acid in the treatment of familial type II hyperlipoproteinaemia.
    Mann JI; Harding PA; Turner RC; Wilkinson RH
    Br J Clin Pharmacol; 1977 Jun; 4(3):305-8. PubMed ID: 197982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Hypolipidemic effect of cholestyramine in patients affected by type II hyperlipoproteinemia].
    Sauvanet JP; Drouin P; Mejean L; Lambert D; Debry G
    Therapie; 1978; 33(5):615-22. PubMed ID: 217121
    [No Abstract]   [Full Text] [Related]  

  • 16. Transport kinetics of plasma free fatty acid, very low density lipoprotein triglycerides and apoprotein in patients with endogenous hypertriglyceridaemia: effects of 2,2-dimethyl, 5(2, 5-xylyoxy) valeric acid therapy.
    Kissebah AH; Alfarsi S; Adams PW; Seed M; Folkard J; Wynn V
    Atherosclerosis; 1976; 24(1-2):199-218. PubMed ID: 182185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypolipidemic drugs and lipoprotein metabolism.
    Levy RI; Langer T
    Adv Exp Med Biol; 1972; 26(0):155-63. PubMed ID: 4370081
    [No Abstract]   [Full Text] [Related]  

  • 18. Dietary and drug treatment of primary hyperlipoproteinemia.
    Ann Intern Med; 1972 Aug; 77(2):267-94. PubMed ID: 4345081
    [No Abstract]   [Full Text] [Related]  

  • 19. Lecithin: cholestrol acyl transfer rate and high density lipoproteins in plasma during dietary and cholestyramine treatment of type IIa hyperlipoproteinaemia.
    Wallentin L
    Eur J Clin Invest; 1978 Dec; 8(6):383-9. PubMed ID: 217692
    [No Abstract]   [Full Text] [Related]  

  • 20. Acute effects of cholestyramine on serum lipoprotein concentrations in type II hyperlipoproteinaemia.
    Olsson AG; Dairou F
    Atherosclerosis; 1978 Jan; 29(1):53-61. PubMed ID: 204317
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.